Replies to post #102837 on Biotech Values

[jbog]

Dewophile,

Basically what you are laying out is a price war and as long as Sanofi feels it's worth their time they will continue to negotiate with the large users.

This is somewhat surprising considering Sandoz's manufacturing limits at this point.

This product just might turn out to be a nice base income from which Momenta can grow and use to pay for its future products rather than the goldmine we were hoping for.

What's unusual in this product rollout is that because Sandoz was the only product approved, Sandoz priced its product high enough that Sanofi could easily attack it. It was Sandoz's original pricing that kept Sanofi in the game.

If more generics were approved originally, at an decent discount, Sanofi probably would have just folded its tent and closed shop.

[zipjet]

(zip- after listening to the presentation i am still unclear if 35% end user penetration achieved or 35% shipped to wholesellers)

I initially asked the lawyer-like question, what the meaning of is is? :-)

Others who I think understand the industry better than I, said Shea was saying they had indeed sold out their capacity.

But for Shea's statement I would have modeled a slower ramp.

These are interesting questions. But the real one is, whether/when TEVA gets approval?

:-)

zip

PS - I largely agree with WSA on how to value the mL profit sharing until we can infer that Teva will not get approved. But over time the inference that Teva will not get approval will rise as will MNTA's stock price.